These stocks might be good candidates for the trash heap.
Here are some new stock additions from our favorite fund managers.
Despite political pressures, two leading fund managers see potential in pharmaceuticals, biotech, and other health-care stocks.
With other areas of the market mired in red ink, drug companies are on track to deliver healthy profits for the first quarter.
Strong underlying growth outweighs $7.5 billion charge.
Biotech leader is setting the stage for accelerated earnings in 2001.
But we think the stock's weakness could be a buying opportunity.
But revenue growth could still be an issue in the short term.
Cost cuts are boosting earnings, but slower-than-expected sales growth is a concern.
Company blows past expectations on strength in key products--again.
Double-digit sales and earnings growth are key to the firm's appeal.
The company is making some good moves, but still faces patent crunch.
Not all the news is negative, but we think it's too early to buy in.
We think there's a lot to like in this company.
But the turnaround won't really take hold until 2002 or later.
There's no way to get around it--loss of Prozac patent is bad.
Neupogen sales weaker than expected--again.
Despite a few negatives, the stock is hard to ignore.
This quarter's results show that it's still a growth powerhouse.
But news on additional diet-drug litigation reserves is a negative.
With non-core business lines weighing down results and a delayed product launch adding uncertainty, investors should take a pass for now.
Despite waning Prozac sales, a lot of things are going right.
Celexa continues to gain market share, but risks remain.
The biotech bellwether isn't fazed by declining Neupogen sales.
But patent expirations continue to cloud drugmaker's stock.
After Vanlev bombshell, merger pressure could increase.
Flush with cash, drug company is hitting targets on core products.
With key products continuing to ramp up market share, the company remains the fastest-growing player in the pharmaceutical group.
Bristol-Myers Squibb is pulling its new drug application for Vanlev, which had been viewed as one of the most promising products in the pharmaceutical industry.
Although the drug giant beat Wall Street estimates, much of its growth was driven by alliance revenues rather than sales gains on its own products.
Drugmaker beats profit forecasts, but loss of Prozac patent looms.
Although the company has some promising products under development, sales and earnings growth are still well below average.
Drugmaker launches another buyback, says earnings gains on track.
Now that Pfizer and Warner-Lambert have joined forces, the drug giant is left alone--but perhaps not for long.
By picking up Warner-Lambert, Pfizer will add to its strengths in cardiovascular disease, central nervous system disorders, infectious disease, and women's health.
This quarter's results underscore the depth of the company's product line.
With most of its products hitting on all cylinders and alliance revenues skyrocketing, the drug company continues to post some of the best growth rates in the industry.